Plain English Summary
Background and study aims
Oesophagogastric cancer refers to cancer of the stomach or oesophagus (also known as the gullet or food pipe). The COG study aimed to compare the effectiveness of an experimental drug called Gefitinib with placebo (dummy) tablets in patients with advanced oesophagogastric cancer. Gefitinib works by blocking an important receptor on the surface of cancer cells called the Epidermal Growth Factor Receptor or EGFR. It has been shown in lung cancer that patients whose tumours have mutations in the gene for EGFR respond very well to Gefitinib treatment. Gefitinib has been shown to be of benefit in some other types of cancer and tumour shrinkage has been demonstrated in some small studies of patients with oesophageal cancer treated with gefitinib. In the TRANSCOG study we are planning to analyse tumour samples for EGFR gene and other similar gene mutations to find out whether their presence in oesophageal cancers can predict which patients will respond and benefit from Gefitinib treatment and which will not. If this is possible we will be able to develop tests to allow us to target treatment to those patients most likely to respond and benefit from this treatment, and in those patients who are unlikely to respond we can avoid using a treatment that will not work and potentially try other treatments which may have a better chance of success.
Who can participate?
Oesophagogastric cancer patients aged over 18 who participated in the COG study.
What does the study involve?
Partcipants will be asked to sign a consent form to allow us to analyse a sample of their tumour tissue that has already been obtained during previous endoscopy and biopsy of your cancer or at the time of previous surgery. Participants will not need to undergo any extra tests, treatments or procedures to participate in the TRANSCOG study.
What are the possible benefits and risks of participating?
At this early point in the research it is very unlikely that the TRANSCOG trial will benefit participants directly, but by taking part in this study researchers will find out more about genetic mutations that cause cancer and mutations which cause tumours to respond (or not respond) to treatment. As the rate of oesophageal cancer is increasing, the gift of providing tumour samples is invaluable to the progression of cancer research. Please note that the analysis performed is a genetic analysis of the tumour and not a genetic analysis of each participant. Consequently, the results will have no implications regarding why participants developed the cancer, or for any of their family members. No extra tests, treatments or procedures are required for participation in TRANSCOG, as the tumour specimens used are those which are ‘left over’ from previous procedures.
Where is the study run from?
Section of Translational Medicine, Division of Applied Medicine at the University of Aberdeen (UK).
When is the study starting and how long is it expected to run for?
October 2011 to December 2012.
Who is funding the study?
Project Grant from the Experimental and Translational Research Committee - Scottish Government Chief Scientist’s Office, NHS Grampian Endowments and Grampian Gastro-oesophageal Cancer Research Fund (GASTROCAN).
Who is the main contact?
Dr Asa Dahle-Smith
asadahle-smith@nhs.net
Trial website
Contact information
Type
Scientific
Primary contact
Dr Asa Dahle-Smith
ORCID ID
Contact details
University of Aberdeen
Polwarth Building
Foresterhill
Aberdeen
AB25 2ZD
United Kingdom
-
asadahle-smith@nhs.net
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
10623
Study information
Scientific title
Qualification of predictive biomarkers for epidermal growth factor receptor tyrosine kinase inhibitor therapy in oesophagogastric adenocarcinoma
Acronym
TRANS-COG
Study hypothesis
TRANS-COG is a translational study involving molecular analysis of tumour samples from patients enrolled in the Cancer Oesophagus Gefitinib (COG) trial (EudraCT: 2007-005391-13, ISRCTN29580179) to identify the predictive and prognostic impact of epidermal growth factor receptor (EGFR) signalling pathway abnormalities and determine their clinical utility as biomarkers to optimise clinical and cost effectiveness of tyrosine-kinase inhibitor (TKI) therapy in oesophagogastric cancer. Mutation analysis of EGFR, KRAS, BRAF and phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) will be performed and EGFR gene copy number determined by fluorescent in-situ hybridisation (FISH). A tissue microarray of trial tumours will be constructed and, Immunohistochemistry (IHC) for EGFR and p-AKT performed.
More details can be found at http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10623
Ethics approval
North of Scotland Research Ethics Committee, 08/08/2011, ref: 11/AL/0372
Study design
Observational clinical study
Primary study design
Observational
Secondary study design
Other
Trial setting
Hospitals
Trial type
Diagnostic
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Upper Gastro-Intestinal Cancer
Intervention
EGFR pathway analysis
Mutational analysis of EGFR, KRAS, BRAF and PIK3CA and EGFR FISH
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measure
Overall survival in different biomarker groups
Secondary outcome measures
No secondary outcome measures
Overall trial start date
01/09/2011
Overall trial end date
31/12/2012
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Patients with oesophagogastric cancer must be eligible for and enrolled in the COG trial
2. Ability to provide written informed consent
3. Formalin-fixed and paraffin-embedded (FFPE) tumour material available
4. Male and female participants
5. Lower Age Limit 18 years
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 300; UK Sample Size: 300
Participant exclusion criteria
1. Patients not enrolled in COG trial
2. Inability to provide written informed consent
3. No FFPE tumour material available for analysis
Recruitment start date
01/09/2011
Recruitment end date
31/12/2012
Locations
Countries of recruitment
United Kingdom
Trial participating centre
University of Aberdeen
Aberdeen
AB25 2ZD
United Kingdom
Sponsor information
Organisation
University of Aberdeen (UK)
Sponsor details
Health Services Research Unit
Polwarth Building
Foresterhill
Aberdeen
AB25 2ZD
United Kingdom
Sponsor type
University/education
Website
Funders
Funder type
Government
Funder name
Scottish Government, Department of Health (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list